|Description||NMS-E973 shows a widespread antiproliferative activity with an average IC50 of 1.6 μM, and induces the degradation of client protein.|
|Brife Description||NMS-E973 is a potent and selective Hsp90 inhibitor with DC50 of <10 nM for Hsp90 binding, no activiy against a panel of 52 diverse protein kinases.|
|Solubility||DMSO: 90 mg/mL warming|
|Storage||3 years -20oC powder, 6 months-80oC in solvent.|
Coumemycin A1 is found to bind at a second ATP-binding site in the C-terminal domain of Hsp90, thus disrupting the dimerization of the Hsp90 complex.IC50 70μmol...
SNX-2112 is an Hsp90 inhibitor which is currently undergoing multiple phase 1 clinical trials. In all cell lines, SNX-2112 led to degradation of MET, HER-2, EGF...
TAS-116 is a inhibitor of Hsp90. It induces significant cytotoxicity in MM cells even in the presence of BMSCs, associates with downregulation of phospho-Akt an...
Radiocicol is an antifungal antibiotic. It inhibits heat Hsp90 activity by binding to the ATP-binding pocket, subsequently suppressing cell transformation induc...
Pochocin D is a patent Hsp90 inhibitor. IC50 80.0nM.
The methlate salt form of PF-04929113 that has potential antineoplastic activity targeting Hsp90. It could probably result in the proteasomal degradation of onc...
EC 114 is a high affinity, potent and selective Hsp90 inhibitor. IC50 1.1 nM. It exhibits selectivity for Hsp90 over Grp94 and TRAP1 (Ki values are 61 and 255 n...
VER-50589 is a potent Hsp90 inhibitor with IC50 of 21 nM for Hsp90β.
CPUY201112 is an N-terminal Hsp90 inhibitor, which leads to decreased expression of Hsp90 client proteins and may result in increased tumor cell apoptosis.
VER-155008 is an adenosine-derived inhibitor of heat shock protein 70 (Hsp70; IC50 = 0.5 µM) that is selective over Hsp90.It targets the nucleotide-binding doma...
Onalespib, also known as AT13387, is a synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic a...
NW-457 is a potent Hsp90 inhibitor with no detectable hepatocytotoxicity in vitro. It synergizes with ionizing irradiation to induce chromatin condensation, nuc...
Alvespimycin hydrochloride is the hydrochloride salt of alvespimycin, an analogue of the antineoplastic benzoquinone antibiotic geldanamycin. Alvespimycin binds...
CH5138303 is a novel and potent Hsp90 inhibitor. CH5138303 showed high binding affinity for N-terminal Hsp90α (Kd=0.52nM) and strong in vitro cell growth inhibi...
SST0116CL1 is a second-generation small molecule inhibitor of Hsp90, which leads to decreased expression of Hsp90 client proteins and reduced tumor cell prolife...
Herbimycin A is an ansamycin antibiotic that acts as a Src family kinase inhibitor. Binds to the SH domain and inhibits the activity of p60v-src and p210BCR-ABL...
Novobiocin is found to bind at a second ATP-binding site in the C-terminal domain of Hsp90, thus disrupting the interaction of both p23 and Hsp70 co-chaperones ...
Alvespimycin (17-DMAG; KOS-1022; NSC 707545) is a potent, H2O-soluble Hsp90 inhibitor with IC50 of 62 nM.17-DMAG displays ~2 times potency against human Hsp90 t...
17-AAG hydrochloride is a potent HSP90 inhibitor with IC50 value of 5 nM, which is a 100-fold higher binding affinity for HSP90 derived from tumour cells than t...
XL888 is an ATP-competitive inhibitor of Hsp90. Through this action, specific client proteins are degraded, leading to cell cycle arrest or apoptosis. XL888 is ...